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ABSTRACT 
 
Chronic hypertension has long been known to cause left ventricular remodeling. 
Although previous studies pointed towards inflammation as the pathological driver of cardiac 
remodeling, the exact mechanistic pathway associated with pressure overload-induced cardiac 
remodeling remains to be elucidated. In order to address this issue, we designed this study to 
determine pathways associated with pressure overload induced cardiac remodeling and identify 
therapeutic targets to attenuate this maladaptive cardiac remodeling.  Rats with surgically 
constricted abdominal aorta were used as an animal model for pressure overload and associated 
Left ventricular (LV) structure and functional changes were measured by pressure-volume 
admittance catheterization. Human cardiac fibroblasts were used to assess the specific 
mechanistic pathways associated with prostaglandin D2 (PGD2) mediated fibrotic response. At 
the 14 day period, pressure overloaded animals showed significant changes in LV structural and 
functional parameters. Cyclooxygenase-2 (COX-2) inhibition with Nimesulide significantly 
attenuated the structural and functional changes associated with LV remodeling due to pressure 
overload. Prevention treatment with Nimesulide showed that the beneficial effects seen with 
acute treatment were still prevalent even after discontinuation of treatment. Intervention 
treatment with Nimesulide showed that only a few parameters like chamber size and stroke 
volume can be revered by COX-2 inhibition in rats with already established LV remodeling. 
Similar results were observed with prevention treatment with HQL-79 a specific H-Prostaglandin 
D synthase inhibitor, indicating that the PGD2 is a major driver for LV remodeling downstream 
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of COX-2. Intervention treatment with HQL-79 showed, selective blockade of H- PGD synthase 
can significantly reverse maladaptive changes in cardiac structure and function indicated by LV 
mass index, chamber size, stroke volume and total collagen levels. In vitro studies on human 
cardiac fibroblasts have shown that both prostaglandin D receptors the DP2 and DP2 receptors 
down-regulate COX-2 expression. DP1 receptor was shown to up-regulate both Collagen 1A and 
3A mRNA expressions, whereas DP2 receptor activation led to elevation of Collagen 1A and 
reduction in collagen 3A mRNA expression. These results indicate that COX-2 and downstream 
PGD2 are major drivers for pressure overload induced cardiac remodeling. H-PGD synthase was 
found to be a potential therapeutic target to prevent and reverse left ventricular remodeling 
induced by pressure overload. 
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INTRODUCTION 
 
Hypertension and heart failure: 
Hypertension is a chronic disorder characterized by sustained elevation in blood pressure. 
Blood pressure can be defined as the pressure exerted on the walls of the arteries which varies 
from the maximum (when the heart starts contracting or cardiac systole) and the minimum (when 
the heart is relaxing or cardiac diastole). Pressure changes of 120/80 mm/Hg (systole / diastolic) 
are considered the normal arterial blood pressure for humans. Based on the severity, 
hypertension can be classified into various stages. 1) Pre Hypertension (120-139/80-89) 2) Stage 
1-hypertension (140-159/90-99) and 3) Stage 2-hypertension (>160/>100). Hypertension is 
commonly categorized into two groups, primary hypertension (idiopathic hypertension) and 
secondary hypertension. Primary hypertension is elevated blood pressure without a known 
etiology. Secondary hypertension is elevated blood pressure due to one or more underlying 
causative disorders like reno-vascular disorders, hormonal imbalance or pregnancy to name a 
few.  
According to the CDC, one in three adults in the United State is believed to be 
hypertensive[1]. In 2008 about 61,000 deaths were directly related to hypertension in U.S. The 
estimated direct and indirect cost of hypertension was nearly 50 billion dollars in 2008[2].  
Hypertension is best known to be the major predisposing factor for congestive heart failure, 
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atherosclerosis and myocardial infarction[3]. Studies have shown that in the blood pressure range 
of 115/75 to 185/115, every 20/10 mm Hg increase doubles the chances of myocardial infarction 
and stroke[4]. In people less than 45 yrs of age, hypertension is shown to be more prevalent in 
males as compared to females, and African Americans were found to be more susceptible to 
hypertension, as compared to white males in United States[5, 6]. According to the data collected 
by the national health and nutrition examination survey between 2005 and 2008, nearly 80 % of 
people with hypertension are unaware that they are hypertensive and roughly 50% of them do 
not have it controlled.  
  The contribution of hypertension to heart failure is greater than any other known risk 
factor[7]. The transition from a hypertensive heart to heart failure is comprised of multiple 
stages. In people with chronic hypertension, Left ventricular remodeling occurs as a 
compensatory change to hemodynamic stress[8]. The initial cardiac remodeling is associated 
with improved contractility of cardiac muscle and maintenance of cardiac output to compensate 
for the elevated ventricular pressure and afterload. However, prolonged stimulus from the 
elevated blood pressure ultimately leads to a decompensated state of dilated cardiaomyopathy, 
eventually leading to heart failure[7].  
 
Left ventricular remodeling: 
Left ventricular remodeling is characterized by alterations in shape, dimensions, mass 
and compliance of the left ventricle due to physiological (i.e. exercise or pregnancy) or 
pathophysiological stress (i.e. hypertension). Physiological cardiac remodeling is associated with 
elevated cardiac performance, where as pathological remodeling is associated with maladaptive 
changes including myocyte hypertrophy and extracellular matrix (ECM) remodeling, leading to a 
 3 
 
loss in chamber size and compliance.  Collagen, the major component of the ECM, is a fibrillar 
protein which forms the scaffolding that provides structural support to myocardial muscle fibers 
and vasculature[9]. Collagen is synthesized by the resident fibroblasts and is deposited in to the 
extracellular space. Although nearly twenty different collagen phenotypes have been identified, 
cardiac ECM is mainly composed of collagen type I and III.  The total collagen, and more 
importantly the ratio of collagen type I to type III determine myocardial tissue properties like 
wall stiffness and compliance[10]. Collagen type I has a higher tensile strength as compared to 
collagen type III. The ratio of collagen type I to collagen type III in the normal left ventricle is 
known to be 1.93     . Studies have shown that during ischemic cardiomyopathy in humans, 
total collagen levels are significantly increased as compared to controls (7.96 +/- 1.24 mg/g to 
13.9 +/- 1.30 mg/g) and there is also a significant reduction in the ratio of collagen type I to type 
III (1.93 +/- 0.52 to 1.23 +/- 0.27) [11]. Collagen type I levels remained the same, where as 
collagen III levels significantly increased (2.56 +/- 0.21 mg/g to 6.10 +/- 0.58 mg/g ) in the 
dilated hearts as compared to normal hearts. In contrast, hypertension induced left ventricular 
remodeling is known to lead to a significant increase in collagen the I to III ratio increasing 
tissue stiffness and reducing compliance, therefore effecting cardiac function[11].   
Another important characteristic of cardiac remodeling is cardiac myocyte cell 
hypertrophy. Cardiac myocytes are multinucleated striated muscle cells made up of numerous 
bundles of myofibrils, which are comprised of repeating units of sarcomeres. Sarcomeres are the 
functional units of the myocytes made up of actin and myosin filaments, which interact with each 
other leading to contraction and relaxation [12]. Compensational hypertrophy of the myocytes 
occurs as a result of  hemodynamic stress[7]. Cardiac myocyte hypertrophy can be divided into 
two group’s concentric and eccentric hypertrophy based on the method of the addition of 
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sarcomeres. Concentric hypertrophy occurs due to the addition of new sarcomeres in parallel to 
old ones, leading to increased wall thickness. Concentric hypertrophy usually occurs during 
pressure overload. In eccentric hypertrophy the newer sarcomeres units are added in series to 
older units, leading to elongation of myocytes. This type of hypertrophy leads to an increase in 
chamber dimension without effecting wall thickness. Eccentric hypertrophy usually occurs in 
response to volume overload to accommodate for increased stroke volumes[9, 12].  
 
The role of TNF-  cardiac remodeling: 
The exact mechanistic pathway(s) responsible for LV remodeling during stress are  
unknown[13]. Various studies point towards inflammation as the major driver for stress induced 
cardiac remodeling.  
Hemodynamic stress is known to stimulate resident cardiac and infiltrating immune cells 
to synthesize and secrete several autocrine and paracrine signaling molecules knows as cytokines 
and interleukins. One of the most commonly studied cytokines associated with cardiac 
remodeling is tumor necrosis factor alpha (TNF-). Several studies have shown elevated levels 
of TNF-in people with heart failure [14, 15], although the exact mechanism behind the 
stimulation of TNF-upregulation is not clearly understood. TNF- is involved in inflammation 
with a myriad of direct effects on cardiac tissue such as LV remodeling, LV dysfunction and 
cardiomyopathy depending on the receptor and the cells stimulated [14, 15]. Mei Sun et al, 
showed significant elevation of TNF-levels in the heart post descending aortic banding and 
TNF- with aortic banding had shown attenuation of LV dysfunction as compared to SHAM 
operated wild type mice. These mice also demonstrated reduced matrixmetalloproteinase-9 
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activity and improved cardiac function. TNF- is known to activate different cell signaling 
cascades leading to various effects which can sometimes be contradictory to each other. 
Condorelli G et al demonstrated the role of AKT / NF-kB and JUN Kinase in TNF- mediated 
neonatal cardiac myocyte hypertrophy. The same group also found that inhibition of AKT / NF-
kB and JUN Kinase pathways did not prevent myocyte hypertrophy indicating complex etiology. 
Although up regulated levels of TNF- is used for heart failure prognosis, there is no evidence of 
beneficial effects of TNF- inhibition on cardiac hypertrophy[14]. 
 
The role of TGF- on cardiac remodeling: 
Another well studied inflammatory mediator associated with LV remodeling is 
transforming growth factor- (TGF-), which has been associated with cardiac hypertrophy and 
excessive collagen production or fibrosis. A study by Lim JY et al  showed that neonatal cardiac 
myocytes treated with TGF- lead to a hypertrophic response via TAK1-MKK3/6-p38 MAPK 
signaling pathways[16]. TGF-receptor antagonism has been shown to attenuate myocardial 
fibrosis in mice with cardiomyopathy[17]. Kuwahara F. et al has shown anti-fibrotic effects of 
TGF- inhibition using anti TGF- antibodies administered IP daily, on pressure overload-
induced cardiac hypertrophy [18]. Although anti TGF- antibodies showed anti-fibrotic effects, 
they had no effect of myocyte cell hypertrophy.  Lucas JA et al demonstrated cardio-myopathic 
effects of TGF- inhibition in pressure overloaded due to significant reduction in collagen 
deposition[19]. Overall, TGF- inhibition attenuates ventricular fibrosis induced by pressure 
overload, but causes possible deleterious ventricular dilation in pressure overloaded hearts [20, 
21].  
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Interleukins and cardiac remodeling:    
Interleukins are pleiotrophic cytokines with a myriad of functions. Earlier studies have 
demonstrated elevated circulating levels of interleukins-1 in essential hypertension[22].  Other 
studies have shown elevated levels of interleukin-6 in patients with heart failure[14]. Interleukin-
6 treatment infusion was shown to cause fibrosis and concentric hypertrophy in Sprague Dawley 
rats, independent of change in blood pressure. Cardiac fibroblasts treated with IL-6 were shown 
to elevate collagen production and phenotypic transformation of fibroblasts to myofibroblasts. 
Although these cytokines have been previously investigated, there remains a distinct lack benefit 
from their inhibition. Besides cytokines (i.e. TNF-, TGF-) and interleukins, the major 
inflammatory modulators are prostaglandins. 
 
Prostaglandins and cardiac remodeling: 
Prostaglandins are fatty acid derivatives composed of 20 carbons with a 5 carbon ring. 
Prostaglandins have a very short half life (seconds to a few minutes) and act via autocrine or 
paracrine signaling. Although prostaglandins are synthesized and secreted in very small 
concentrations (pico-nano molar concentrations), they have significant biological impacts such 
as inflammatory mediation and hormonal regulation.  Prostaglandins have a myriad of effects 
depending on the type of receptors expressed in the tissue(s) and the prostaglandins involved. 
Prostaglandins are known to cause vasodilatation or vasoconstriction depending on the tissue and 
prostaglandins involved Platelet aggregation, control cell growth and thermoregulation. One of 
the most prominent effects of prostaglandins is the initiation of the inflammatory response to 
stress or toxic stimulus leading to pain and fever. Prostaglandins are also associated with certain 
 7 
 
cardiovascular effects like cardiomyocyte cell hypertrophy and fibrosis depending on the specific 
prostaglandin. The biochemical precursor for all prostaglandins is arachidonic acid. Arachidonic 
acid is cleaved from the phospholipids in the cell membranes by the action of enzyme 
phospholipase A2. Cyclooxygenase enzymes catalyze the conversion of arachidonic acid into 
prostaglandin H2, which is a precursor for all other prostaglandins such as prostaglandin E2, 
prostaglandin F2, prostaglandin I2 and thromboxanes. Prostaglandin H2 is converted 
enzymatically into all other prostaglandins by the actions of specific individual synthases which 
are expressed in a tissue specific manner.  
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Role of COX-2 and remodeling: 
The main regulators of prostaglandin synthesis are the cyclooxygenase group of enzymes. 
Three different types of cyclooxgenases have been identified to date, COX-1 COX-2 and COX-
3. COX-3 was later found to be a splice variant of COX-1. Until recently COX-2 is thought to be 
an inducible enzyme, as opposed to the constitutively expressed COX-1. However, research in 
the last decade showed the constitutive expression of COX-2 in various tissues. Numerous 
studies were done to evaluate the role of COX activity and inhibition on cardiac remodeling in 
models of infarction and heart failure. 
LaPointe MC et al. showed that COX-2 inhibition significantly attenuated the cardiac 
hypertrophy and collagen deposition post myocardial infarction induced by ligation of the left 
anterior descending coronary artery in mice[23]. Parecoxib, a selective COX-2 inhibitor was also 
found to be beneficial in improving cardiac function in the rat model of ischemic heart failure by 
significantly attenuating cardiac myocyte apoptosis and preserving vascularity. Delgado et al. 
showed a significant improvement in overall mortality and left ventricular remodeling with 
COX-2 inhibition in a doxorubicin model of heart failure in rats[24]. While COX-2 inhibition 
was found to be beneficial in improving cardiac function, the mechanistic pathway(s) involved 
are not known. In particular, there are no studies describing the role of specific COX-2 inhibitors 
on pressure overload induced cardiac remodeling. The chronic COX-2 inhibition was also 
associated with various adverse effects including renal hemodynamic complications due to an 
altered balance between Prostaglandin I2 and the thromboxanes[25]. Rofecoxib, a selective 
COX-2 inhibitor has been withdrawn from clinical use after VIGOR (Vioxx GI Outcomes 
Research) study indicated a significant increase in cardiovascular and renal complications after 
chronic selective COX-2 inhibition. One of the known causes for hemodynamic complications 
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associated with COX-2 inhibition is the reduction in vascular prostacyclin levels leading to 
imbalance between anti-thrombotic PGI2 and pro-thrombotic thromboxane A2, leading to 
cardiovascular thrombotic events[26].  
Because COX-2 inhibition leads to global down regulation of all prostaglandins leading 
to cardiovascular adverse effects, identifying a specific prostaglandin involved in cardiac 
remodeling would help identify a novel therapeutic target for drug development aimed at 
preventing cardiac remodeling without precipitation of significant adverse cardiac events. 
Although the cardiovascular effects of individual prostaglandins in other cardiovascular 
disorders are recently coming to light, the specific cardioprotective or adverse roles of 
prostaglandins and their mechanistic mode of action in attenuating pressure overload (PO) 
induced cardiac remodeling is still relatively unknown. 
 
Prostaglandin E2 in remodeling: 
PGE2 is biosynthesized by action of Prostaglandin E synthases (PGE synthases) on 
prostaglandin H2. PGE2 is known to act via the binding to one of its four G protein coupled 
receptors (EP1– 4) resulting in various biological effects such as vasodilation, smooth muscle 
relaxation, thermoregulatory effects on CNS, sodium excretion and hemodynamic regulation. 
Compared to all other prostaglandins, Prostaglandin E2 is most widely studied for its role in the 
cardiovascular system. The Gi coupled EP3 receptor was demonstrated to have anti fibrotic 
effects, but was also associated with pro-hypertrophic activity.  Studies conducted on neonatal 
cardiac myocytes by Mendez et al. has shown that the antihypertrophic actions of COX-2 
inhibitors are mediated through inhibition of PGE2 formation[27]. Mendez et al later 
demonstrated that the PGE2 receptor induced hypertrophic effects were mediated by an EP4 
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receptor subtype via the p42/44 MAPK pathway[28]. Recently, cardioprotective and 
antihypertrophic effects of PGE2 were reported after reperfusion injury[29]. Moreover, 14 week 
old cardiac specific EP4 receptor knockout mice showed impaired cardiac function and was also 
associated with attenuated cardiac remodeling post myocardial infarction[30]. Although EP4 
knockout mice were found to be cardioprotective post myocardial infarction, a longitudinal study 
done on 23-33 week old male and female rats by Harding et al. showed that cardiac specific EP4 
knockout rats developed decreased cardiac function and developed cardiomyopathy[31].   
 
Prostaglandin F2 in remodeling: 
Prostaglandin F2 is known to act via its G protein coupled (Gq) FP receptor expressed in 
the cardio-vasculature leading to increased intracellular calcium levels. mRNA expression 
studies on left ventricular tissues have shown that the expression of FP receptors was the highest 
compared to all other prostaglandin receptors[32]. Prostaglandin F2 was found to induce 
hypertrophy in neonatal cardiac myocytes through its receptor (FP)[33]. This was further 
confirmed by Lai et al in adult cardiac myocytes[34].In vivo administration of Fluprostenol, a 
stable analog of PGF2 which a potent FP receptor agonist was found to cause cardiac 
hypertrophy which is evident from elevated LV mass index. The pro-hypertrophic actions of FP 
receptor activation were linked to the MEK-ERK2 signaling cascade[35]. Recent studies 
investigated stable certain stable metabolites of PGF2 such as 8-epi-prostaglandin F2α as 
important biomarkers for severity of heart failure and cardiac function in humans (). The role of 
PGF2 and its receptors in cardiac remodeling secondary to pressure overload is currently 
unknown; although FP receptor might have an active role in mediating stress induced cardiac 
remodeling, elucidating it is not in the scope of this study.   
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Prostaglandin I2 in remodeling: 
Prostaglandin I2 (PGI2) which is also known as prostacyclin is biosynthesized by the 
action of both COX-1 and COX-2. The G protein coupled prostacyclin receptor; IP is known to 
be widely expressed in the cardio-vasculature and acts via the Gs subunit to elevate intracellular 
cAMP levels. Activation of its receptor (IP) has shown to have antihypertrophic effects. IP 
-/-
 
knockout animals have shown to have significantly elevated PGI2 was shown to have 
cardioprotective effects in ischemia/ reperfusion model in mice [36] . As compared to the sham 
operated controls, IP
-/- 
knockout mice also demonstrated elevated cardiac myocyte hypertrophy 
in mice with pressure overload induced by abdominal aortic constriction [37]. In contrast, IP 
receptor activation by the PGI analog Cicaprost, failed to cause cardiac hypertrophy suggesting 
the role of atrial natriuretic peptide in PGI mediated cardiac hypertrophy.  A study done by 
Francois et al demonstrated that IP
-/-
 in SHR rats led to significant cardiac hypertrophy as 
compared to wild type controls (). It is important to note that the potential therapeutic use of 
PGI2 agonists could be limited due to vascular side effects seen from imbalances between PGI2 
and thromboxane A2 (TXA2) as seen in the case for selective COX-2 inhibitors such as Vioxx
TM
, 
which inhibit downstream PGI2 along with other prostaglandins without affecting TXA2[38]. 
 
 
Prostaglandin D2 in remodeling: 
Prostaglandin D2 (PGD2) biosynthesis is regulated by two specific synthases; 
hematopoietic prostaglandin D synthase (H-PGD synthase) and lipocaline prostaglandin D 
synthase (L- PGD synthase) on Prostaglandin H2. PGD2 has two G protein coupled receptors, 
DP1 and DP2 both of which are present in the heart. DP1 receptor is linked to Gs  (increasing 
cAMP) and is known to inhibit cytokine release and chemotaxis. The DP2 receptor is known to 
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act via Gi (decreasing cAMP) and promote cytokine release and chemotaxis[39]. The role of 
PGD2 and its receptors in cardiovascular system during pathological stress is still unclear. 
According to Gupte et al. in a stressed myocardium the levels of prostaglandin D2 undergo the 
greatest elevation compared  to all other prostaglandins[40]. Schuligoi et al has shown that H-
PGD synthase mRNA expression was significantly increased in the heart post lipopolysaccharide 
(LPS) treated inflammation model in mice [41]. Similar results were found in our lab which 
showed an increase in H-PGD synthase protein levels after 14 day post pressure overload in 
rats[42]. These findings point towards a specific inflammatory pathway involving PGD2 and its 
specific receptors in mediating stress induced cardiac remodeling. Therefore, the goal of this 
study is to establish the potential cardioprotective effects of H-PGD synthase inhibition and the 
pathway(s) involved.  
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MATERIALS AND METHODS: 
 
Drugs used: 
Nimesulide: Nimesulide (Tocris Bioscience
TM 
(Bristol, UK)) is a selective COX-2 inhibitor with 
IC50 of 70M for COX-1 and 1.27M for COX-2 (at 20mg arachidonic acid substrate[43]. 
Nimesulide (Nime) was used at a dose of 25 mg/kg/day in 10% ethanol administered 
subcutaneously.  
 
HQL 79: HQL 79 (Caymen Chemicals
, 
Ann Arbor, MI) is a selective hematopoietic -
Prostaglandin D synthase (H-PGD synthase) inhibitor with an IC50 of 6 M.  HQL 79 was orally 
administered with 0.5% methylcellulose in saline at a dose of 1 mg/kg/day. 
 
BW245C: BW245C (Caymen Chemicals, Ann Arbor, MI) is a selective DP1 receptor agonist. 
BW245C was used at a concentration of 0.1mM in 10 % ethanol. 
 
BWA868C: BWC245C (Caymen Chemicals, Ann Arbor, MI) is a selective DP2 receptor 
antagonist with a Ki of approximately 1.7nM. BWA245C was used at a concentration of 0.1 mM 
in 10 % ethanol. 
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13, 14- di hydro- 15-keto PGD2:  13, 14 dihydro-15-keto PGD2 (Caymen Chemicals, Ann 
Arbor, MI) is a metabolite of prostaglandin D2 and specifically agonizes the DP2 receptor. 13-14- 
di hydro- 15-keto PGD2 was used at a concentration of 100M in 10% ethanol. 
 
BAY u3405: BAY u3405 (Caymen Chemicals, Ann Arbor, MI) is a specific DP2 receptor 
antagonist with an IC50 of 100-170 nM. It has also been documented to have mild thromboxane 
receptor antagonist properties. BAYU3405 was used at a concentration of 100mM in 10% 
ethanol.  
 
GW9662: GW9662 (Caymen Chemicals, Ann Arbor, MI) is potent PPAR gamma receptor 
antagonist with an IC 50 of 3.3nM. This compound acts as antagonist for PPAR alpha and PPAR 
delta with IC 50 of 32nM and 2000nM respectively. GW9662 was used at a concentration of 
100M in 10 % ethanol.  
 
U0126: U0126 (Caymen Chemicals 
TM 
(Ann Arbor, MI)) is a selective MEK ½ inhibitor with 
IC50 values of 72 nM and 58 nM respectively. U0126 was used at a concentration of 100mM in 
10 % ethanol.  
 
PGD2: prostaglandin D2 was obtained from Caymen Chemicals 
TM 
(Ann Arbor, MI). 
 
PGJ2: Prostaglandin J2 was obtained from Caymen Chemicals, Ann Arbor, MI). 
All other chemical reagents were obtained from fisher scientific
 
(st louis, MO) unless otherwise 
specified. 
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Methods: 
Animals used:  
Adolescent male Sprague Dawley rats were used for the studies. Rats were housed in a standard 
colony room with controlled temperature (22  ), and 12h light/12h dark cycles. Food and water 
were provided ad libitum. All procedures involving animals were approved by the Institutional 
Animal Care Use Committee of the University of Mississippi according to the National Institutes 
of Health Guide for Care and Use of Laboratory Animals.  
 
Surgical induction of pressure overload:  
Pressure overload was induced by means of aseptic survival surgically induced 
abdominal aortic constriction. Anesthesia was induced and maintained using isoflurane gas 
anesthetic at a flow rate of 2.5l/min. Animals were placed on a heated pad at 37°c during the 
procedure to help maintain core body temperature. Under aseptic conditions, a one inch incision 
was made on the linea alba (to minimize blood loss) slightly below the xiphoid process. The 
animals were then disemboweled and the abdominal aorta was identified.  A zero silk ligature 
was passed under the abdominal aorta in between the left and right renal artery. A blunt 22 gauge 
needle was then carefully placed on the abdominal aorta and tightly constricted using the silk 
ligature. The needle was quickly removed leading to the coarctation of the abdominal aorta to the 
external diameter of the 22 gauge needle. Post constriction, bowels were moved back into the 
abdominal cavity and the musculature was closed using an absorbable suture (Chromic 3-0). The 
skin incision was closed with skin staples. The rats were left to recover in a heated recovery unit. 
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Assessment of cardiac function: 
In vivo left ventricular chamber volume and functions was assessed using the Scisense 
ADVantage
TM 
(Ontario, Canada) pressure volume admittance catheter. Anesthesia was induced 
in the animals using isoflurane gas anesthetic in an induction chamber and was maintained with 
Sodium Pentobarbital IP. A small mid line neck incision was made and blunt dissection was 
done to identify the carotid artery. After the distal blood flow in the isolated region of the carotid 
was controlled by ligation and the proximal end was suspended with a silk ligature at tension to 
prevent blood flow. A small incision was made and the pressure/volume (P/V) catheter was 
carefully placed in the carotid artery.  A zero silk ligature was tied around the blood vessel 
around the catheter to prevent blood loss. The catheter was then advanced into the left ventricle 
via the carotid artery.  Data was analyzed using iWorx© (Dover, NH) Labscribe Instrument 
software. Mean Arterial Pressure was calculated as Diastolic pressure + 1/3(Systolic pressure – 
Diastolic Pressure. Max dP/dt, the peak rate of maximal pressure rise, was reported as an 
indicator of contractility. The slope of the End Diastolic Pressure Volume Relationship 
(EDPVR) was reported as an indicator of passive tissue property (e.g. ventricular compliance, 
thus, the steeper the curve, the greater the ventricular stiffness).  Min dP/dt, peak rate of pressure 
decline over time, and Tau, the isovolumic relaxation constant, provided indices of ventricular 
relaxation.     
 
Tissue collection: 
After the animals by were euthanized by surgical isolation of the hearts under deep 
anesthesia; the heart, kidneys and blood were collected; left and right ventricles were identified 
and isolated. The mass of the ventricles and each kidney were weighed. The apical regions of the 
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heart were collected and snap frozen in nitrogen for protein analysis. The septal wall of mid 
section of the heart was isolated and used for HPLC analysis of Prostaglandin D2, prostaglandin 
J2 and prostaglandin F2 alpha. The tissue from the non-septal mid section was used to measure 
the total collagen using hydroxyproline analysis. 
 
Protein Extraction: 
The apical regions of the left ventricles were used for protein analysis. 100mg of LV 
tissue was measured and placed in 800l of homogenizing buffer (1X protease inhibitor cocktail, 
PBS). The tissues were homogenized using a hand held tissue homogenizer. 80 L of cell lysis 
buffer (10% PBS-Tween) was added and the homogenate was centrifuged for 30 mins at 
16000rpm. The supernatant was collected and used for protein analysis. 
 
Protein Quantification: 
Total protein quantification was done using DC
TM 
protein assay (Bio-Rad, Hercules CA). 
Bovine serum albumin in PBS protein standards concentrations ranging between 0.1g/l and 
4g/l were prepared 0.5 l of protein extracts and standards (in triplicates) were loaded in a 96 
well plate. 200ml of reagent A and 25 ml of reagent B provided by the manufacturer were added 
to each well. As per the instructions absorbance corresponding to protein concentration was 
measured at 750nm.  
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Hydroxyproline analysis for total collagen:  
The mid section (non-septal region) of the left ventricular tissue (50 mg) was dried in an 
80 °C oven and then hydrolyzed in 6 N HCl at 110 
o
C for 18 hr. After hydrolysis, samples were 
decolorized using 2mg of activated charcoal. The charcoal was then filtered, and the filtrate dried 
using vacuum rotary evaporator. The samples were re-suspended in specified citrate buffer and 
the hydroxyproline concentration was determined using the method described by Woessner[44]. 
 
Western blotting: 
  Gel electrophoresis (12% SDS-PAGE) is carried out with the left ventricular (LV) tissue 
and cell extracts at 200 V for 45 mins. The proteins were then transferred onto a nitrocellulose 
membrane using a semi-dry transfer apparatus. The blots were probed with rabbit polyclonal 
antibodies specific to COX-2, H-PGD synthase, DP1 or DP2 and an internal normalization 
control (GAPDH). Anti-rabbit goat secondary antibody tagged with horseradish peroxidase was 
added to the primary antibodies and blots were visualized using ECL chemiluminiscent reagent 
on the Versadoc
TM
 imaging apparatus (Bio-rad
TM
). 
 
ELISA (enzyme linked immune sorbent assay): 
Commercially available ELISA kits were used to assess the protein concentrations of 
TNF- and TGF-  (R and D systems, Minniapolis, MA). TNF  ELISA was carried out by 
loading 50 l of rat tissue followed by dilution with 50 l of calibrator diluents provided in the 
kit into each well of the ELISA plate (pre coated with monoclonal TNF-) and incubated for 2 
hrs. Rat TNF- conjugate solution was added as recommended. After the addition of the 
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substrate solution the absorption was measured at 450nm with a correction at 570 nm. Results 
were reported as ng/ml, a similar procedure was employed using corresponding TGF-
monoclonal antibodies to detect the levels of TGF-levels in the LV extracts. 
 
Cell culture:  
Primary human cardiac fibroblasts cells (HCF) were obtained from Sciencell
 
(Carlsbad, 
CA). The cells were grown in DMEM supplemented with 10% Fetal bovine serum (Cellgro, 
Manassas, VA), and 5 % Neonatal calf serum (Sciencell), Fibroblast growth serum (Sciencell), 
5g / ml Plasmocin Prophylactic (Invivogen, San Diego, California) and 1X Antibiotic – 
Antimycotic solution (Cellgro, Manassas, VA). HCFs were grown in 100 mm cell culture dishes 
containing fibroblast growth media. When the cells reached 80% confluence, they were serum 
starved for 24 hrs in 2% fetal bovine serum. Depending on the assay and drug treatment, the cells 
were treated for 45 mins or 48 hrs in growth media. At the end of treatment, the cells were 
scraped in 1x cell Lysis buffer (cell signaling
TM
, Danvers, MA), supplemented with protease 
inhibitor cocktail. Cells solutions were sonicated and centrifuged. The extracts were for further 
protein analysis as described above.  
 
COX-2 cell based ELISA (Human / Mouse Total COX-2 Immunoassay): 
10000-20000 cells per well in 200l of media were plated in each well of a 96 well plate 
and were allowed to attach incubated overnight at 37 °C. The media was replaced with serum 
starve media after the cells reached 90% confluence. The cells were then treated with the various 
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compounds of interest in a total volume of 200l. The cells were fixed with 4% formaldehyde 
for 30 mins. After fixation, blocking reagent (Bovine serum albumin) was added to all wells and 
incubated for 2 hrs; the blocking reagent was then replaced with 100l of provided antibodies 
specific to COX-2 and GAPDH were added to the wells. After addition of specific signaling 
reagents provided by the manufacturer, fluorescence was measured as per manufacturer 
recommendations (R&D systems).   
 
Collagen gene expression analysis:  
HCF cells were seeded in 12 well plates at 4x10
6 
cells per well in 3ml media and treated 
with the various compounds at specified doses for 48 hrs. Cells were lifted using 0.5ml of trypsin 
and centrifuged to form a pellet and were, washed with PBS, and RNA was isolated with the 
RNeasy Mini kit (Qiagen, Valencia, CA).  Up to 500 ng of cDNA were reverse transcribed with 
the qScript cDNA SuperMix (Quants Bio Sciences) prior to quantitative real-time PCR detection 
on the Bio-Rad CFX connect thermocycler with FAM-labeled TaqMan primers were obtained 
from Applied Biosystems (Carlsbad, CA) for Collagen I and III.  VIC-labeled GAPDH TaqMan 
primers were also obtained from Applied Biosystems (Carlsbad, CA); the ΔΔCt method was 
used to calculate changes in expression, normalized to the appropriate time-matched vehicle-
treated control cells. 
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AIM: 1 
 
Efficacy of acute selective COX-2 inhibition using Nimesulide on 
attenuating pressure overload induced cardiac remodeling. 
 
Introduction: 
It is established that pressure overload is associated with structural and functional 
maladaptative remodeling of the left ventricle [12]. Although the specific molecular pathway 
leading to maladaptive remodeling is unknown, previous studies suggest inflammation is a key 
component in stress induced maladaptive cardiac remodeling[13]. Specific inhibition of COX-2, 
which is responsible for the enzymatic conversion of arachidonic acid to PGH2 a precursor for 
the synthesis of all prostaglandins has been demonstrated to attenuate maladaptive cardiac 
remodeling in animal models of heart failure and myocardial infarction[23, 24]. Although several 
studies point towards beneficial effects of COX-2 inhibition, clinically chronic COX-2 inhibition 
is limited due to adverse effects linked to their use.  Reviews by Moodley and Mukherjee have 
documented that the renal and vascular adverse effects of chronic COX-2 inhibition are due to 
altered balance of certain prostacylins and thromboxanes on prolonged use of COX-2 
inhibitors[25]. These cardio-renal adverse effects were linked with chronic clinical usage of 
COX-2 inhibitors. If acute treatment with COX-2 inhibitors is found to be beneficial, we 
therefore hypothesize that they can be clinically used to attenuate cardiac remodeling in the early 
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stages of hypertension without precipitating adverse effects associated with chronic COX-2 
inhibition. 
 
Rationale: 
  The effect of acute COX-2 inhibition on attenuating the structural and functional changes 
associated with pressure overload induced myocardial stress is currently unknown. We designed 
this study to evaluate changes in the chamber dimension and function, along with other 
biochemical parameters such as COX-2 expression, Collagen expression and PGD synthase 
expression in the LV secondary to pressure overload from acute COX-2 inhibition. Based on the 
studies that support a cardioprotective role for selective COX-2 inhibitors in other models of 
heart failure [13,14,15], we hypothesized that such COX-2 inhibition would attenuate the 
remodeling induced by pressure overload. Identifying a short term treatment strategy during the 
initial stages of remodeling could potentially prevent the early maladaptive cardiac remodeling 
that is responsible for the loss of cardiac function, without precipitating chronic treatment 
induced adverse effects and represent a significant change in the current treatment paradigm.    
 
Objective: 
  Study the effects the selective COX-2 inhibition using Nimesulide in attenuating cardiac 
remodeling on pressure overloaded rats at the 14 day time period. 
Approach: 
Nine week old Sprague Dawley rats were housed under standard environmental 
conditions (12 hr light/12 hr dark) and fed commercially available chow and tap water ad 
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libitum. Surgical induction of pressure overload was achieved by performing a coarctation of the 
abdominal aorta between the left and right renal arteries.  Treatment groups included 1) sham-
operated surgical control group (SHAM); 2) untreated pressure overloaded (PO) group and 3) 
Nimesulide treated (NIME) pressure overload group (25mg/kg/day s.q.). Treatment was initiated 
one day prior to induction of pressure overload and was continued till day 14 post surgery. 
NIME treated – sham operated controls and vehicle treated (10% ethanol) controls were also 
included. Cardiac structural (chamber size, LV mass) and functional (stroke volume, Max dP/dt, 
Tau coefficient, end diastolic pressure volume relationship (EDPVR)) parameters were assessed 
on day 14 using a Scisense (Scisense Inc, Ontario, Canada) admittance catheter. Myocardial 
COX-2 and H-PGD synthase levels were assessed by western blotting. Myocardial L-PGDs 
levels were assessed using ELISA. Myocardial total collagen levels were assessed by 
hydroxyproline assay for total collagen. One way ANOVAs were performed using GraphPad 
Prism software (GraphPad Software, San Diago, CA). All grouped data are expressed as means 
of +/- SEM, unless otherwise mentioned. Grouped data comparisons were performed using one 
way ANOVA with bonferroni post hoc test. Statistical significance was taken to be p<0.05. 
 
Results: 
Relative to age-matched SHAM, 14 day untreated PO and 14 day NIME treated animals 
had significant reduction in body mass (Table 1). The significant reduction is body weight post 
surgery is consistent with surgical stress. 14 days post induction of pressure overload, LV mass 
of PO animals was found to be significantly elevated, as compared to the sham controls. 
Nimesulide treatment significantly attenuated this pressure overload-induced increase in LV 
mass. The increase in LV mass is still significant vs SHAM animals when the mass is 
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normalized to body weight. Nimesulide treatment significantly attenuated this change. Right 
ventricular mass did not show any significant difference in PO rats as compared to SHAM 
controls. The right kidney mass was not significantly affected by pressure overload surgery 
whereas the left kidneys showed a significant reduction in mass post-pressure overload, as 
compared to the SHAM control. Significant reduction in left kidney mass is most likely due to 
reduced blood flow to the left kidney due to the arterial coarctation (Table 1). 
 
Table 1: Comparison of body weights, LV, RV and kidney wet weights in 14 – day post 
surgery. 
Parameters: 
in vivo conductance 
catheter 
Sham-Operated 14-day untreated PO 14- day NIME treated 
Body weight (g) 335 ± 5 284±8* 296 ± 9* 
LV mass (mg) 752 ± 5 839 ± 27* 739 ± 19¥ 
LV/Body weight 
Ratio 
2.2 ± 0.01 2.9 ± 0.1* 2.5 ± 0.03* 
RV mass(mg) 181 ± 6 170 ± 6 155 ± 5* 
Rt Kidney mass (mg) 1107 ± 28 1222 ± 117 1131 ± 73 
Lt Kidney mass (mg) 1099 ± 22 658 ± 43* 755 ± 67*¥ 
Table 1: Comparison of body weights, LV, RV and kidney wet weights in 14 – day post surgery 
sham-operated, PO and PO + NIME groups.*Denotes P ≤ 0.05 compared with sham.¥ Denotes P 
≤ 0.05 compared with untreated PO. Values are reported as mean ± SEM (n≤7).  
 
Heart rate was unchanged in PO rats, but significantly elevated in the NIME animals  as 
compared to sham-operated animals. Mean arterial pressure was significantly increased in both 
PO groups, as compared to SHAM but it is attenuated by NIME intervention, this which was 
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consistent with the elevated LV end systolic pressures in the PO groups (Table 2).  Left 
ventricular end diastolic pressure was not different between any of the groups. Multiple indices 
of systolic performance (i.e. max dP/dt, stroke work, and preload recuitable stroke work (PSRW) 
were significantly increased in the untreated PO group relative to SHAM control. Of these 
functional parameters, Stroke work was increased by 53% in the untreated PO group compared 
to Sham values. Treatment with Nimesulide significantly attenuated stroke work compared to the 
untreated PO group. 
Left ventricular end systolic and diastolic volumes were significantly reduced in the 
untreated PO group relative to SHAM (Table 2).  Treatment with NIME prevented the PO-
induced changes in these parameters and fully attenuated them to SHAM levels. Tau, an 
indicator of LV relaxation rate, was markedly increased in the PO hearts but preventative 
treatment with NIME significantly attenuated the PO induced change. Ventricular stiffness as 
measured by the slope of the end diastolic pressure volume relationship (EDPVR) trended to be 
significantly higher in the PO group as compared to the SHAM animals; this change was 
significantly attenuated by NIME treatment.  
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Table 2: Structural and functional parameters of 14 day controls, PO and NIME treated 
animals. 
 
 
Parameters: 
in vivo conductance catheter 
Sham – operated 
14-day untreated 
PO 
14-day Nimesulide – 
treated PO 
Heart rate (bpm) 324 ± 8 342 ± 15 363 ± 9* 
End systolic pressure (mmHg) 121 ± 3 177 ±  9* 170 ± 8* 
End diastolic pressure 
(mmHg) 
4 ± 0.3 3 ± 0.5 4 ± 0.6 
Mean arterial pressure 
(mmHg) 
115 ± 7 155 ± 4 * 141 ± 5 *¥ 
End systolic volume (l) 193 ± 17 127 ± 15 * 226 ± 9¥ 
End diastolic volume (l) 331 ± 14 281 ± 16* 324 ± 15 ¥ 
Stroke work (mmHg x mL) 14,303 ± 1430 21900 ± 2203* 13906 ± 1232¥ 
PRSW (mmHg) 58 ± 9 83 ± 9 * 93 ± 10* 
Max dp/dt (mmHg/s) 7367 ± 182 10801 ± 457 * 10064 ± 494* 
Min dp/dt (mHg/s) -7096 ± 440 -9044 ± 745* -10195 ± 247* 
EDPVR 0.027 ± 0.01 0.039 ± 0.01 0.028 ± 0.01¥ 
Tau (Galantz) 14 ± 0.3 18 ± 1.4* 13 ± 0.4¥ 
 
Table 2: Systolic and diastolic parameters in 14 days post surgery sham-operated , PO and PO + 
Nime groups via in vivo conductance catheter.*Denotes P ≤ 0.05 compared with sham.¥ Denotes 
P ≤ 0.05 compared with untreated PO. Values are reported as mean ± SEM. 
 
 27 
 
Figure 1: Analysis of total myocardial COX-2 Protein expression in the14 day SHAM, PO 
and NIME treated groups.          
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Figure 1: Analysis of total myocardial COX-2 Protein expression SHAM, PO and NIME treated 
groups (n≥7). Values are reported as mean ± SEM. (* denotes p<0.05 compared to SHAM, 
**denotes p< 0.02 compared to SHAM). 
 
Compared to SHAM controls, PO animals did not show significant alteration in 
myocardial COX-2 protein expression levels.  NIME treatment significantly reduced COX-2 
protein expression as compared to both the SHAM and PO groups (Figure 1). Furthermore, 
significant up regulation of myocardial H-PGD synthase was observed in PO vs Sham animals. 
This increase was significantly attenuated in the NIME group (Figure 33).  
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Figure 2: Analysis of total myocardial collagen expression in the14 day SHAM, PO and 
NIME treated groups.          
                    
      
Figure 2: Analysis of total myocardial collagen expression in sham-operated (SHAM), Pressure 
overloaded (PO) and Nimesulide treated groups (NIME). n≥6 per group. Values are reported as 
mean ± SEM (* denotes p<0.05) 
      
Compared to SHAM controls, PO animals showed significant increase in total collagen 
levels, as indicated by the hydroxyproline assay for total collagen (figure 2). The collagen levels 
in NIME group were not significantly different from either the PO group or the SHAM groups. 
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      Figure 3: Analysis of H-type PGD synthase expression in the14 day SHAM, PO and 
NIME treated groups.          
                
 
Figure 3: Analysis of total myocardial H-type PGD synthase expression in sham-operated 
(SHAM), Pressure overloaded (PO) and Nimesulide treated groups (NIME). n≤6 per group. 
Values are reported as mean ± SEM. (* denotes p<0.05) 
 
 
Discussion: 
Previous studies have linked inflammation as the key component of stress induced 
cardiac remodeling [9]. COX-2, one of the prominent mediators of inflammation was found to be 
significantly elevated in the models of ischemia / reperfusion models of myocardial stress. In the 
setting of pressure overload, our results show no change in the myocardial levels of COX-2 
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enzyme after 14 days of pressure overload although treatment with the COX-2 specific inhibitor 
Nimesulide (NIME) significantly reduced myocardial COX-2 protein levels. This NIME effect is 
consistent with other investigations that demonstrated a positive feedback via downstream 
prostaglandins in favor of expression of COX-2, and not COX-1. Specifically PGE2 and 15-J-
PGD2 were shown to induce COX-2 mRNA expression. 15-J-PGD2 is a non-enzymatic 
degradation product of PGD2. PGD2 is synthesized from PGH2 by the action of its specific 
synthases Hematopoietic-prostaglandin D synthase (H-PGD synthase) and Lypocaline 
Prostaglandin D synthase (L-PGD synthase). Our study showed a marked increase in Myocardial 
H-PGD synthase and a marked decrease in L-PGD synthase in PO group at day 14 post induction 
of pressure overload as compared to the SHAM controls.  Previous studies found that changes in 
prostaglandin levels are associated with estrogenic cardioprotection [45, 46].
   
Specifically, L-
PGD synthase expression is regulated by the β subclass of estrogen receptors (ER), which are 
found in both myocytes and cardiac fibroblasts[47].  Strong evidence exists that removal of the 
ovaries, and a subsequent loss of estrogen ER- dependent loss of cardioprotection against 
adverse remodeling, and abolishes myocardial L-PGD expression as well. A similar phenomenon 
was documented by Tokudome et al[48]. Where the authors investigated the beneficial effects of 
dexamethasone (glucocorticoid receptor agonist) during cardiac ischemia/reperfusion injury.  GR 
activation reduces infarct size; however, this effect was greatly diminished in L-PGD deficient 
mice.
 
 Combining these studies with our own findings suggests that a reduction in L-type PGD 
may promote adverse cardiac remodeling. 
It is documented that the potential for cross-over effects between individual prostaglandin 
receptor systems and various prostaglandins exists[49]. Moreover, these mediators often work in 
concerted pairs to bring about agonist and antagonist effector activities even within the 
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cardiovascular system. Further, the response of individual gene expression to decreased feedback 
from the ultimate product formation may in one instance promote further expression of the target 
gene or bring about a reduction in gene expression depending upon the promoter system 
associated with the target gene.  H-PGD and L-PGD synthase are commonly expressed in 
separate organ systems throughout the body, but are yet co-expressed in the heart. While 
Nimesulide has been extensively characterized as a selective COX-2 inhibition [50, 51] there has 
been no study to date of any interaction with a PGD synthase. It is plausible that Nimesulide is 
mediating effects on specific PGD synthases as well as altering their expression patterns. The 
current study did not explore these potential directs effects they remain as potential mechanism 
to explain our findings. 
Pressure overload is associated with resultant changes in hemodynamic and mechanical 
load leading to increased myocardial stress.  After two weeks, systolic function was enhanced in 
the pressure overload group, as indicated by maximum dP/dt, preload recruitable stroke work, 
and end systolic pressure.  The use of the selective COX-2 inhibitor Nimesulide concordant with 
PO induction did not affect arterial blood pressure or cardiac contractility.  However, Nimesulide 
did attenuate changes in LV mass and chamber morphology. Herein, we report PO-induced 
changes in Tau, EDPVR, and collagen content indicative of adverse changes in passive tissue 
properties, which were attenuated by COX-2 inhibition.  Previous reviews have documented the 
role of increased wall stress as a driving factor for ventricular remodeling[52, 53].Our previous 
work has shown that early treatment to prevent adverse LV remodeling in the initial phase has 
beneficial effects to extend the compensated state even when the treatment is discontinued[54].   
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Conclusion: 
 Ventricular remodeling due to PO induced by abdominal aortic coarctation was 
associated with hypertrophy, fibrosis, and altered chamber morphology after 14 days. These 
changes in LV tissue properties were attenuated by selective COX-2 inhibition. Acute increase in 
myocardial expression of H-type PGD synthase, as well as a decrease in L-type PGD synthase 
were also associated with pressure overload induced cardiac remodeling. Long-term selective 
inhibition of COX-2 uncouples the normal relationship between COX-1 and COX-2 derived 
prostaglandins, promoting vasoconstriction and thrombosis and limiting chronic use. Our study 
suggests there is a cardioprotective effects associated with acute inhibition of COX-2 with 
pressure overload, a model of early hypertension. Short term administration of a COX-2 
inhibition to newly diagnosed hypertension patients beginning anti hypertension therapy may 
offer a clinical benefit. Alternatively, selective targeting of PGD isomerase(s) may lead to more 
specific and effective therapeutic treatment without harmful side effects.  
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AIM: 2 
 
To investigate the efficacy of Prevention and intervention treatment 
strategies of selective COX-2 inhibition on left ventricular maladaptive 
cardiac remodeling induced by pressure overload. 
 
 
Introduction:  
Our work has demonstrated that at the 14 day time period pressure overload leads to significant 
left ventricular hypertrophy, remodeling and fibrosis. These changes were significantly 
attenuated with global COX-2 inhibition by Nimesulide treatment; establishing its therapeutic 
potential in preventing pressure overload induced cardiac hypertrophy. The 14 day COX-2 
inhibition study does not explore the progression of remodeling once the treatment is stopped 
(Prevention) or the potential role of COX-2 inhibition in reversing already established cardiac 
remodeling (Intervention).   
Rationale: 
Although acute COX-2 inhibition was found to be beneficial in attenuating maladaptive 
structural and functional changes associated with pressure overload, further knowledge is 
essential to assess the clinical significance of COX-2 inhibitors against maladaptive remodeling.  
Taking into account the side effects of chronic selective COX-2 inhibition, limiting the long-term 
use, the acute treatment is only clinically significant only when the beneficial effects persist even 
  
34 
 
after the discontinuation of treatment. Also, in most clinical cases early detection of hypertension 
is uncommon. Hence, it is essential for a therapeutic treatment to stop and/or potentially reverses 
already established remolding. We designed the prevention treatment strategy study to 
investigate the preservation of cardiac function for 14 days after discontinuation of acute 
treatment (14 days) with a selective COX-2 inhibitor (Nimesulide) during the initial period of 
hypertension in rats. This would help establish the long term beneficial effects of acute COX-2 
inhibition on pressure overload induced cardiac remodeling. Intervention is a more clinically 
useful treatment strategy is designed to assess the role of COX-2 inhibition at reversing already 
established cardiac remodeling.  
Experimental Approach: 
The study was performed on 9 week old male Sprague Dawley rats. Pressure overload was 
surgically induced by performing an abdominal aortic constriction as described earlier. The study 
will include four groups (n=8/group) 1) Sham-operated group (SHAM) 2) Untreated pressure-
overload group (PO) 3) Nimesulide (25mg/kg/day s.q.) prevention treated group (Prevention) 
and 4) Nimesulide (25mg/kg/day s.q.) intervention treated group (Intervention).  
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The prevention group involved initiation of Nimesulide treatment one day prior to the 
surgical induction of hypertension and is continued till day 14. On day 14 the treatment was 
stopped and the animals were allowed to progress under PO for another 14 days (Figure 4). For 
the intervention group, treatment was initiated on day 14 post-induction of pressure overload and 
was continued till day 28 when the ventricles show significant remodeling. On day 28, a 
Scisense (Scisense Inc, Ontario, Canada) admittance catheter was used to determine various left 
ventricular structure and functional parameters including ESP, EDP, EDV, LV mass, max DP/dt, 
Tau coefficient, and EDPVR. LV tissue extracts were used for protein analysis by western 
blotting to measure the levels of COX-2, H-PGD synthase and L-PGD synthase levels were 
Figure 4: Study treatment strategies. 
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measured using ELISA (Caymen Chemicals). Total myocardial levels of collagen were 
determined using hydroxyproline assay.  
 
Results:  
Table 3: Structural and functional parameters of 28 day controls, PO, NIME prevention 
and NIME intervention treated animals. 
 
Parameters: 
in vivo 
conductance 
catheter 
Sham – 
operated 
28-day 
untreated PO 
28 -day Nimesulide 
– treated Prevention 
28 –day Nimesulide 
treated Intervention 
Body weight (gm) 363±6 353 ± 6 348 ± 2 361±9 
LV Wt (mg) 792 ± 21 1010 ±  17* 898 ± 50 920±48* 
LV/Bdy Wt Index 2.2± 0.04 2.9 ± 0.1* 2.6 ± 0.1* 2.5±0.1* 
Mean arterial 
pressure (mmHg) 
124 ± 8 163 ± 13 * 177 ± 6 * 144±9* 
End diastolic 
volume (l) 
282 ± 20 185 ± 13 * 272 ± 25¥ 233±27 ¥ 
Stroke volume 
(l) 
200 ± 13 143 ± 10* 208 ± 11 ¥ 205±16 ¥ 
Max dp/dt 
(mmHg/s) 
8136±621 10560±472* 10672±226* 10479±800* 
Tau (Galantz) 14±0.6 19±1.5* 17±1.7 16±0.7 
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Table 2:  Comparison of Body Wt,LV structural and functional parameters in sham –operated (SHAM) 
,untreated pressure overload (PO), PO+NIME prevention and intervention treatment strategies(n≤6 per 
group). Values are reported as mean ± SEM. *p ≤ 0.05 vs. Sham. ¥ = p ≤ 0.05 vs. PO. 
 
There was no significant change in body mass in any PO animals or treated animal, with 
or without NIME as compared to sham. Mean arterial pressure (MAP) was found to be 
significantly elevated by PO, as compared to SHAM, and was attenuated, but not fully reversed 
by intervention (Table 3). The untreated PO group showed significant elevation in LV mass (best 
indicated by a 24 % increase in the LV/bdy weight index), suggesting LV hypertrophy. This 
increase in mass is associated with decrease in LV chamber size (approximately 34.5% reduction 
in EDV compared to SHAM controls). Prevention treatment significantly prevented elevation of 
LV mass which was maintained after discontinuation of treatment. Intervention treatment 
successfully reversed already established increase in LV mass (Table 3).  
 
Stroke volumes in PO animals were lower by approximately 29% as compared to SHAM 
controls, indicating a loss of chamber size. The loss of stroke volume was significantly 
attenuated by both Prevention and Intervention treatment demonstrated the potential for both 
persistant changes and a reversal of ventricular remodeling. PO also significantly increased 
myocardial contractility, as indicated by Max dP/dt, and loss of tissue compliance, indicated by 
Tau. Prevention treatment significantly prevented the loss of tissue compliance without altering 
myocardial contractility (see specific Aim 1 results) and these effects persisted 14 days post 
discontinuation of treatment. Similarly stroke volume in Intervention animals was significantly 
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higher than in PO animals, intervention treatment with Nimesulide. Intervention treatment 
significantly reversed the loss of tissue compliance without effecting contractility (Table 3).  
 
Figure 5: Analysis of total myocardial COX-2 Protein expression in the 28 day SHAM, PO, 
NIME prevention and NIME intervention treated groups.          
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Figure 5: Analysis of total myocardial collagen expression in sham-operated (SHAM), Pressure 
overloaded (untreated PO), Nimesulide treated prevention and Nimesulide treated intervention 
groups (n≤7 per group). (* denotes p<0.05, Compared to sham, # denotes p<0.05, Compared to 
untreated PO). Values are reported as mean ± SEM 
 
The total collagen levels measured using the hydroxyproline assay showed a significant 
elevation of total myocardial collagen in PO animals as compared to SHAM controls (Figure 5). 
Prevention treatment blocked this fibrotic response (see specific Aim 1 results) and the beneficial 
effects were still significant 14 days after discontinuation of treatment. Intervention treatment 
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with failed to restore the elevated collagen levels. This indicates that once the initial remodeling 
has already occurred the intervention treatment would only restore certain parameters like stroke 
volume and Max dP/dt, without affecting other maladaptive changes in LV mass, EDV and total 
collagen levels. 
 
Discussion:  
Our previous work demonstrated that at the 14 day time period animals with pressure 
overload show significant maladaptive LV remodeling[55]. This includes increased LV mass 
along with a reduction in LV chamber size. The heart also showed significant increase in total 
collagen levels indicating fibrosis. Along with these structural changes, several functional 
parameters such as loss of tissue compliance, increased contractility and reduced stroke volumes 
were observed. Nimesulide treatment was found to be beneficial in attenuating these changes 
when given for the whole study period of 14days. The prevention and intervention treatment 
strategies were designed to study the efficacy of Nimesulide treatment on long term progression 
of remodeling and its potency to reverse already established remodeling respectively. The 
Prevention model is setup to explore the continuity of benefit afforded should PO persist after 
COX-2 inhibition is stopped. It was demonstrated that the, attenuation of LV mass index is still 
significant even 14 days after discontinuation of treatment. This suggests that early treatment 
with selective COX-2 inhibitors could block initial maladaptive remodeling and these results are 
still significant even after discontinuation of treatment. Along with attenuating structural 
maladaptations, prevention treatment also helped retain compliance of LV tissue and increase 
contractility leading to preservation of stroke volume and cardiac output. Prevention treatment 
also helped attenuate LV fibrosis as indicated by maintenance of total collagen levels in LV 
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tissue. These results suggest that a novel treatment strategy involving addition Nimesulide to the 
normal anti-hypertensive treatment prescribed to patients recently diagnosed hypertension, could 
prevent the maladaptive remodeling associated with hypertension without precipitating adverse 
effects associated with chronic Nimesulide administration. The intervention treatment with 
Nimesulide successfully reversed already established increase in LV mass index and loss of 
chamber size. As evident from mean arterial pressure values, beneficial effects of Nimesulide 
treatment were not due to lowering of blood pressure. Intervention treatment with Nimesulide 
also showed significant reduction in already established loss of tissue compliance without 
effecting contractility. Intervention treatment on the other hand failed to reverse established 
fibrosis in the left vertical. Based on these results, acute treatment with Nimesulide can be 
clinically significant in reversing pathological changes in certain parameters effecting cardiac 
function such as elevation in LV mass and reduction in chamber size.  
 
Significance: 
The results of the prevention and intervention treatment has shown that acute treatment 
with  specific COX-2 inhibitors might be of great clinical significance in preventing and 
reversing cardiac remodeling induced by pressure overload.  
 
 
 
 
  
41 
 
AIM: 3 
 
To investigate the efficacy of two treatment strategies of selective 
Hematopoietic Prostaglandin D synthase inhibition on left ventricular 
maladaptive cardiac remodeling induced by pressure overload. 
  
Introduction: 
Cyclooxygenase-2 catalyzes the conversion of arachidonic acid to prostaglandin H2. 
Subsequently, all other prostaglandins are biosynthesized by the action of their specific synthases 
from the common precursor prostaglandin H2. Various prostaglandins such as PGE2, PGF2 and 
their specific receptors are being studied to evaluate their cardio-protective roles. Currently there 
is no literature that evaluated the cardio-protective role of PGD2. Studies by Gupte et al showed 
that the levels of PGD2 were the most elevated in a stressed myocardium as compared to other 
prostaglandins[40]. Consistent with these findings, our previous studies (Aim 1) also 
demonstrated that pressure-overload induced myocardial stress leads to significant up regulation 
of H prostaglandin D synthase[42]. As previously mentioned, H-PGD synthase and L-PGD 
synthase are the two specific synthases which catalyze the conversion of prostaglandin H2 to 
Prostaglandin D2. In Aim 1, we demonstrated that attenuation of cardiac remodeling by 
Nimesulide treatment was associated with a significant down regulation of myocardial H-PGD 
synthase levels[42]. In addition to these findings PGJ2 the endogenous metabolite of PGD2 was 
also associated with cardio-protective effects. The non-enzymatic downstream metabolite of 
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PGJ2, 15- deoxy–PGJ2 is the endogenous ligand for peroxisome proliferator activator receptor 
gamma (PPAR-).Studies showed that PPAR- receptor activation in pulmonary and renal 
tissues leads to fibroblast proliferation collagen deposition and cytokine release[56, 57]. This 
also suggests that PGD2 plays an essential role in mediating pressure overload induced cardiac 
remodeling and the beneficial effects associated with Nimesulide treatment were due to 
subsequent reduction in PGD2 levels. The potential cardio protective effects of selective blocking 
of these synthases in order to reduce PGD2 expression are currently unknown. Thus we 
hypothesized that H-PGD synthase inhibition may prove to be a more specific target to attenuate 
cardiac remodeling as compared to global prostaglandin inhibition by COX-2 inhibitors. 
Therefore we proposed this study to understand the effects of H-PGD synthase inhibition by 
prevention and intervention treatments on pressure overload induced cardiac remodeling.  
 
Rationale:  
Chronic specific COX-2 inhibition is known to cause renal and cardiovascular 
complications due to altered balance between the pro and anti-thrombotic actions of 
thromboxanes and prostacyclins, respectively. Selective COX-2 inhibition leads to inhibition of 
global prostaglandin synthesis through the inhibition of the common precursor PGH2. The 
elevation of PGD2 levels in the stressed myocardium as demonstrated by Gupte et al and the 
elevation of H-PGD synthase levels in hypertensive rats (AIM 1) as demonstrated in our study; 
point towards PGD2 as an important mediator of pressure overload induced cardiac remodeling.  
Specific H-PGD synthase inhibition would block the synthesis of Prostaglandin D without 
effecting biosynthesis of any other prostaglandins. It is known that the side effects associated 
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with chronic selective COX-2 inhibition are due to global prostaglandin inhibition. Specific 
inhibition of prostaglandin D synthase could help elucidate the cardioprotective role of blocking 
PGD2 synthesis on attenuating cardiac remodeling without the potential side effects associated 
with COX-2 inhibition. Prevention treatment with specific H- PGD synthase inhibitors was 
designed to evaluate the efficacy of H-PGD synthase inhibition in preventing cardiac remodeling 
induced by pressure overload and the persistence of its effects after discontinuation of treatment. 
The Intervention treatment strategy with H-PGD synthase inhibitor HQL 79 is designed to study 
the efficacy of PGD2 inhibition on reversing already established remodeling. 
 
Approach: 
Five groups with 8 animals (Nine week old Sprague dawley rats) per group were used: 1. 
Sham-operated group (SHAM); 2. Untreated pressure overload group (PO); 3. H-PGD synthase 
inhibitor (HQL 79, Tocris Biosciences
TM
) treated (10/mg/kg/day oral gavage) group 4. 
Prevention HQL 79 treated PO group 5. Intervention HQL 79 treated PO group. Prevention 
treatment group involves initiation of treatment with HQL 79 one day prior to induction of 
pressure overload and continued till day 14 post surgery. Intervention treatment was initiated 14 
days post induction of pressure overload and is continued till day 28. On day 28 various cardiac 
structural and functional parameters like LV mass, EDV, ESV, ESP, Max DP/dt and Tau will be 
assessed using the pressure volume conductance catheter. Total levels of extracellular collagen 
are determined using hydroxyproline assay. HPLC analysis will be done to measure the levels of 
prostaglandin (i.e, PGI, PGE, PGD).   
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Results: 
 
Table 4: Structural and functional parameters of 28 day controls, PO, HQL 79 prevention 
and HQL 79 intervention treated animals. 
 
Parameters: 
in vivo 
conductance 
catheter 
SHAM – 
operated 
28-day 
untreated PO 
28 -day HQL 79 
treated Prevention 
28 –day HQL 79  
treated Intervention 
Body weight (gm) 376±6 347 ± 5 356 ± 7 357±11 
LV Wt (mg) 756 ± 17 989 ±  32* 795 ± 41¥ 916±35* 
LV/Bdy Wt Index 2.0± 0.04 2.8 ± 0.1* 2.2 ± 0.1¥ 2.5±0.1* 
Mean arterial 
pressure (mmHg) 
124 ± 9 163 ± 8 * 152 ± 5 * 164±11 
End diastolic 
volume (l) 
326 ± 20 231 ± 18 * 338 ± 30¥ 317±20¥ 
Stroke volume (l) 152 ± 13 106 ± 10* 159 ± 9 151±18 ¥ 
Max dp/dt 
(mmHg/s) 
8181±470 10369±860* 9274±520* 10560±591* 
Tau (Mirsky) 13±0.7 17±0.8* 14±0.5 18±1.8 
 
Table 3: Comparison of Body Wt, LV structural and functional parameters in sham –operated 
(SHAM) ,untreated pressure overload (PO), PO+HQL prevention and intervention treatment. 
strategies. Values are reported as mean ± SEM (n= 7 per group) *p ≤ 0.05 vs. Sham. ¥ = p ≤ 0.05 
vs. PO. 
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Compared to the SHAM controls, PO animals showed a 28.5% increase in LV/bdy wt 
index and 30% decrease in end diastolic volume and stroke volume. Prevention treatment with 
the specific H – PGD synthase inhibitor HQL 79, significantly attenuated the PO induced 
increase in LV mass index, decrease in stroke volume and decrease in EDV. Intervention 
treatment with HQL 79 significantly recessed the increase in LV mass index and loss of chamber 
volume as indicated by end diastolic volume (Table 4).  
Compared to SHAM controls, PO animals showed a 35% increase in MAP. Neither 
prevention treatment nor the intervention treatment affected the PO-induced increase in MAP. 
PO animals also showed a significant increase in maxdP/dt (contractility) and Tau (relaxation 
coefficient) as compared to SHAM controls. The prevention treatment significantly prevented 
the increase in Tau even 14 days after discontinuation of treatment. Whereas, intervention 
treatment did not affect either Max dP/dt or Tau coefficients as compared to untreated PO 
animals. Total collagen levels measured using hydroxyproline assay were markedly higher (30 
%) in PO animals as compared to SHAM controls. In both HQL 79 prevention and intervention 
treatment groups the collagen levels were found to be significantly attenuated as compared to the 
PO groups (Figure 6). 
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Figure 6: Analysis of total myocardial COX-2 Protein expression in the 28 day SHAM, PO, 
HQL prevention and HQL intervention treated groups. 
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Figure 6: Analysis of total myocardial collagen expression in sham-operated, Pressure 
overloaded, HQL treated prevention and HQL treated intervention groups. Values are reported as 
mean ± SEM. n≤6 per group (* denotes p<0.05, Compared to sham, # denotes p<0.05, Compared 
to untreated PO). 
 
 
Discussion:  
Our previous work demonstrated the efficacy of a selective COX-2 inhibitor in 
attenuating the maladaptive remodeling induced by pressure overload[55]. Nimesulide treatment 
has shown to have persistent cardio protective effects on preventing and reversing cardiac 
remodeling, but failed to reverse already established fibrosis. COX-2 inhibition in the clinic  was 
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associated with renal and cardiovascular complications due to chronic global prostaglandin 
inhibition[58].  Prevention treatment with HQL 79 significantly preserved cardiac structure as 
evident from LV mass index and end diastolic volumes even after discontinuation of treatment. 
Intervention treatment was successful in reversing already established structural changes 
associated with pressure overload. These changes were not associated with the elevated MAP 
due to pressure overload, suggesting the cardioprotective effects of HQL treatments were not due 
to any anti hypertensive effect of drug treatment. Along with preservation of structure, 
prevention treatment also maintained various functional parameters like stroke volume and tissue 
compliance, even 14 days after the discontinuation of treatment. This suggests that acute early 
treatment with HQL 79 might be beneficial in attenuating early remodeling response in pressure 
overloaded rats. Intervention treatment failed to reverse loss of tissue compliance as evident from 
the Tau values. Results from prevention and intervention treatments suggest that HQL 79 
treatment is efficacious in both preventing and reversing already established fibrosis as evident 
from the total myocardial collagen levels. HQL 79 treatment showed effects similar to COX-2 
inhibition with Nimesulide on PO induced cardiac remodeling. This suggests that the myocardial 
stress induced by pressure overload leads to elevated levels of prostaglandin D synthesis via 
increased levels of its specific synthase, H-PGD synthase. These increased levels of 
prostaglandin D2 might be driving the remodeling response through its specific receptors.  
 
Conclusion 
The prevention and intervention treatments with HQL 79 showed that selective blockade 
of H-PGD synthase can prevent and reverse cardiovascular remodeling induced by pressure 
overload. Our previous studies demonstrated that selective COX-2 inhibition can prevent and 
reverse various structural and functional aspects of maladaptive remodeling. Taking into 
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consideration the clinical failure of selective COX-2 inhibitors and their associated adverse 
effects, H-PGD synthase inhibition seems to be a more selective treatment strategy as compared 
to COX-2 inhibitors to prevent and/or reverse PO induced cardiovascular remodeling. Currently 
there is limited literature on the role of prostaglandin receptors DP1 and DP2 on cardiac 
remodeling. In order to better understand the therapeutic potential of H-PGD synthase inhibition 
a complete understanding of the mechanistic pathways associated with DP1 and DP2 receptors 
need to be elucidated. 
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AIM: 4 
 
To elucidate the role of DP1 and DP2 receptors on cytokine expression 
and extracellular remodeling in Human cardiac fibroblasts. 
 
Introduction: 
Our in vivo studies demonstrated that cardiac remodeling induced by pressure overload 
can be prevented using COX-2 selective inhibitor (Nimesulide) and selective prostaglandin D 
synthase inhibitors (HQL 79). These findings suggest that pressure overload-induced cardiac 
remodeling was mainly mediated via prostaglandin D receptors in myocardium. Previous studies 
have demonstrated that prostaglandin D receptors (DP1 and DP2 receptors) are expressed in the 
cardiac myocytes and fibroblasts[39]. The DP1 receptor is a G protein coupled receptor linked to 
the cAMP increasing Gs and it is known to inhibit cytokine release and chemotaxis. In contrast, 
the DP2 receptor is a GPCR coupled to Gi (decreases cAMP) that  promotes cytokine release and 
chemotaxis [39]. To date, little is known about the DP1 and DP2 receptors and their role in the 
myocardium. 15 – d PGJ2 is the endogenous ligand for PPAR  receptors, which are associated 
with fibrosis and heart failure.15-d PGJ2 has been shown to bind to DP2 receptors with higher 
affinity than PPAR  receptors[39]. Our previous studies have shown that, Nimesulide treatment 
is associated with down regulation of COX-2 enzyme expression in rat hearts (AIM 1). The role 
of DP1 and DP2 receptors in regulating COX-2 expression or the downstream actions of PGD2 in 
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the remodeling myocardium has yet to be elucidated. Our preliminary findings suggest thatPGD2 
plays a vital role in cardiac remodeling via its receptors DP1 and DP2.  This study was designed 
to elucidate the specific roles of PGD2 activation of DP1 and DP2 receptors in modulating 
maladaptive remodeling during the pathophysiological stress.  
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AIM: 4-1 
 
To investigate the dose dependent effects of PGD2 on Human cardiac 
fibroblasts. 
Rationale:  
Our previous studies demonstrated that specific inhibition of H-PGD synthase using HQL 
79, leads to significant attenuation of pressure overload induced cardiac fibrosis in rats. Cardiac 
fibroblasts are solely responsible for collagen expression in the heart. To date, there have been 
no studies performed to investigate the effects of PGD2 on human cardiac fibroblasts. In order to 
evaluate the specific role of DP1 and DP2 receptors on cytokine expression and fibrosis it is 
essential to characterize the dose dependent effects of PGD2 on cardiac fibroblasts.  
Approach:  
Human cardiac fibroblasts (HCF) were obtained from Scienecell
TM 
(Carlsbad, CA). The 
HCF cells were treated with a 2-log range of PGD2 doses 100nM, 1M, 10 M for 24 and 48 hrs 
in order to determine the resulting changes in collagen transcription and COX-2 expression 
respectively. COX-2 expression was measured using a cell based Elisa (R  D systems). 
Analysis of collagen I and III mRNA expression was measured using qRT-PCR.  
Results: 
COX-2 enzyme expression, measured using a COX-2 cell based ELISA showed a 
significant downregulation of COX-2 expression with all given doses of PGD2 (10
-8
, 10
-7
 and 10
-
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6
M), as compared to untreated control (Figure 7). Collagen IA (COL1A) and IIIA (COL3A), 
were measured by qPCR; mRNA expression was found to be un-altered with all given doses of 
PGD2 as compared to untreated controls. 
 
Figure 7: PGD2 dose response on COX-2 expression. 
 
Figure 7: Comparison of COX-2 expression in control, different concentrations(PGD2 10
-8
 , 10
-7
 , 
10
-6 
M)  treated HCF cells. Values are reported as mean ± SEM * = p<0.05 vs. control. 
 
Discussion: 
The downregulation of COX-2 expression observed during treatment of HCF cells with 
PGD2 might be due to a feedback regulation via DP1 and/or DP2 receptor signaling. This effect 
might also be mediated via or downstream 15-d PGJ2 acting via PPAR-or DP2 mediated 
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signaling or without a receptor mediated pathway.  COL1A and 3A mRNA levels were found to 
be unaltered by PGD2 treatment. This suggests that PGD2 expression might not alter the 
expression of COL1A and COL3A mRNA expression. Further studies are required to elucidate 
the specific roles of DP1 and DP2 receptors on collagen expression and COX-2 expression in 
order to better understand the role of PGD2 in cardiac remodeling.  
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AIM: 4-2  
 
Investigate the specific role of DP1 receptors on PGD2 mediated effects 
in human cardiac fibroblasts. 
 
Rationale: 
  Although it is known that PGD2 has two specific receptors DP1 and DP2, it is not clear 
which of these receptors plays a role in pressure overload induced cardiac remodeling and 
fibrosis. This study was designed to investigate the specific role of DP1 receptor activation in 
altering COX-2 expression and collagen deposition using selective DP1 receptor activating (BW 
245C, Cayman chemicals
 TM
) and blocking (BWA868C, Cayman chemicals
 TM
) compounds. 
Previous studies have shown to have an IC50 of 250nM for BW245C [59, 60] and ki of 1.7nM for 
BW848C [32, 33]. 
Approach:  
Five treatment strategies were employed in order to assess the role of DP1 mediated 
effects on cardiac fibroblasts:  
1. HCF cells incubated with PGD2 (100 nM) 
2. Treatment with DP1 receptor agonist (BW245C, 1M); 
3. Co-incubation of PGD2 (100nM) with DP1 receptor agonist (BW245C, 1M);  
4. Treatment with DP1 receptor blocker (BWA868C, 0.3M).  
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5. Co-incubation of PGD2 (100nM) and DP1 Receptor blocker (BWA868C, 0.3M);  
Appropriate vehicle controls were also included in the study. The cells were incubated 
with the above mentioned treatment strategies for 24 and 48 hrs in order to elucidate collagen 
mRNA expression and COX-2 expressions respectively. The receptor blockers were added 30 
mins prior to the addition of agonists. COX-2 expression levels were assessed using the cell 
based COX-2 Elisa assay previously mentioned. Changes in gene expression of collagen type I 
and III was measured using multiplexed qRT-PCR.  
 
Results: 
 Figure 8 : DP1 receptor mediated effects on COX-2 expression. 
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Figure 9 : Comparison of COX-2 expression in control, PGD2 treated HCF cells, DP1 receptor 
agonist (BW245C), BW245C+PGD2 10-7, DP1 receptor blocker (BWA868C), BWA868C+ 
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PGD2 10-7. Values are reported as mean ± SEM. * = p<0.05 vs. control and # = p<0.05 vs.PGD2 
10-7 
 
 
Figure 9: DP1 receptor mediated effects on COL 1A mRNA expression. 
 
Figure 10: Comparison of Collagen 1A mRNA expression in untreated control, PGD2 treated 
HCF cells, DP1 receptor agonist (BW245C), DP1 receptor blocker (BWA868C), BWA868C+ 
PGD2 10-7. Values are reported as mean ± SEM.* = p<0.05 vs. control. 
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As previously noted, COX-2 expression was significantly downregulated by 100nM 
PGD2 treatment as compared to untreated controls (figure 8). Similar, significant downregulation 
in COX-2 expression was observed when HCF cells were treated with the DP1 receptor agonist 
BW245C (Figure 8). Co-incubation of HCF cells with DP1 receptor agonist and PGD2 showed 
significant downregulation in COX-2 expression similar to the results observed with BW245C 
treatment. Co-incubation of cells with DP1 receptor antagonist BW868C and PGD2 showed 
similar attenuation of COX-2 down regulation by PGD2.  
As seen previously, treatment with PGD2 did not affect the expression of COL1A in HCF 
cells, as compared to the untreated controls (Figure 9). However, treatment with the DP1 receptor 
agonist, BW245C, significantly elevated the mRNA expression of COL1A, as compared to the 
controls. Treatment with DP1 receptor antagonist BWA868C did not alter COL1A mRNA 
expression, Nor did co-incubation with PGD2 and BWA868C.  
COL3A mRNA levels were also unaltered by PGD2 treatment, as compared to untreated 
controls (Figure 10). Similar to the findings with COL1A, COL3A mRNA levels were 
significantly elevated upon treatment with DP1 receptor agonist BWA245C, as compared to 
untreated controls. Neither, treatment with DP1 receptor antagonist BW868c, or co-incubation of 
BWA868C with PGD2, affected COL3A expression as compared to the untreated controls. 
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Figure 10: DP1 receptor mediated effects on COL 3A mRNA expression. 
 
 
Figure 11: Comparison of Collagen 3A mRNA expression in control, PGD2 treated HCF cells, 
DP1 receptor agonist (BW245C), DP1 receptor blocker (BWA868C) and BWA868C+ PGD2 10-
7. Values are reported as mean ± SEM. * = p<0.05 vs. control and # = p<0.05 vs.PGD2 10-7. 
 
COL3A mRNA levels were also unaltered by PGD2 treatment, as compared to untreated 
controls (Figure 10). Similar to the findings with COL1A, COL3A mRNA levels were 
significantly elevated upon treatment with DP1 receptor agonist BWA245C, as compared to 
untreated controls. Neither, treatment with DP1 receptor antagonist BW868c, or co-incubation of 
BWA868C with PGD2, affected COL3A expression as compared to the untreated controls. 
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Discussion: 
Prostaglandins were previously known to have regulatory effects on upstream COX-2 
expression [61]. Certain prostaglandins such as PGF2 and 15-d PGJ2 (a non-enzymatic 
downstream product of PGD2) were previously shown to downregulate COX-2 enzyme 
expression[61]. In the current study, COX-2 expression was downregulated by PGD2 at 
nanomolar concentration in HCF cells. A similar downregulation was observed when HCF cells 
were treated with DP1 receptor agonist and with co-incubation of PGD2 and 
BWA245C.Furthermore, the blockade of PGD2 mediated COX-2 downregulation by DP1 
receptor antagonist BWA868C. These results suggest that PGD2 functions to decrease COX-2 
expression through the activation of the DP1 receptor. Although, the effects observed during 
specific blockade of DP1 receptor might also be due to DP2 receptor activation by 15-J PGD2 the 
non enzymatic downstream product of PGD2.which is known to have a higher affinity to DP2 
receptor as compared to PPAR  receptor. 
Our in vivo studies have shown that pressure overload leads to an elevation of total 
myocardial collagen levels, and this was correlated with an elevation of H-PGD synthase protein 
levels. Treatment with PGD2 on HCF cells did not alter the levels of collagen type 1A or 3A 
mRNA levels. COL1A and COL3A mRNA expression was significantly elevated when HCF 
cells were treated with DP1 specific receptor activator BW245c. Treatment with DP1 receptor 
antagonist showed no change in either COL1A or COL3A  mRNA expression. These results 
indicate that DP1 receptor activation by PGD2 might be responsible for elevated total myocardial 
collagen levels in rats post pressure overload. 
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AIM: 4-3 
 
To compare the effects of treatment of specific DP2 receptor agonist and 
antagonist to PGD2 treatment in Human cardiac fibroblasts.  
 
RATIONALE: 
This study was designed to evaluate the role of DP2 receptors in the remodeling response 
by cardiac fibroblasts using specific DP2 receptor agonizing (13, 14 dihydro-15-keto PGD2, 
Cayman chemicals 
TM
, Ki value 36 nM)[62, 63] and antagonizing peptides (BAYU3405, Cayman 
Chemicals TM , IC50 of 100 nM)[64, 65]. 
Approach : 
Five treatment strategies were used: 
1. HCF cells incubated with PGD2 (100 nM)  
2. Treatment with DP2 receptor agonist (13, 14 dihydro-15-keto PGD2, 1mM); 
3. Co-incubation of PGD2 with DP2 receptor agonist (13, 14 dihydro-15-keto PGD2, 
1mM); 
4. Treatment with DP2 receptor blocker (BAYU3405, 1mM). 
5. Co-incubation of PGD2 (100nM) and DP2 Receptor blocker (BAYU3405, 1mM); 
  Appropriate untreated and vehicle controls were also included in the study groups. The 
cells were incubated with the above mentioned compounds for 24hrs for elucidate collagen 
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mRNA expression and 48hrs to assess COX-2 expressions. The inhibitors were added 30 mins 
prior to the addition of agonists. COX-2 expression levels were assessed using a cell based COX-
2 Elisa KIT (R and D Systems
TM
). Gene expression analysis of Collagen 1A and 3A mRNA 
expression was measured using multiplexed qRT-PCR.  
Results: 
Figure 11: DP2 receptor mediated effects on COX-2 expression. 
 
Figure 12: Comparison of COX-2 expression in control, PGD2 treated HCF cells, DP2 receptor 
agonist (13, 14 dihydro-15-keto PGD2), 13-14 keto PGD2 + PGD2 10
-7
, DP1 receptor blocker 
(BAYU3405), BAYU3405+ PGD2 10
-7
.Values reported as mean ±SEM. * = p<0.05 vs. control 
and # = p<0.05 vs. PGD2 10
-7
. 
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Figure 12: DP2 receptor mediated effects on COL 1A mRNA expression. 
 
 
Figure 13: Comparison of Collagen 1A mRNA expression in control, PGD2 treated HCF cells, 
DP2 receptor agonist (13, 14 dihydro-15-keto PGD2), DP2 receptor blocker (BAYU3405), 
BAYU3405+PGD2 10
-7
. Values reported as mean ±SEM. n ≥ 5 per group * = p<0.05 vs. control 
and # = p<0.05 vs.PGD2 10
-7
. 
 
 
Compared to controls, 100nM prostaglandin D2 treated cells shows significant down 
regulation of COX-2 as seen before (Figure 11). Treatment with DP2 receptor agonist (13, 14-
dihydro-15-keto PGD2) also significantly down-regulated COX-2 protein expression, to levels, 
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comparable to PGD2. Co-incubation with 13, 14-dihydro-15-keto PGD2 and PGD2 unexpectedly 
attenuated COX-2 down-regulation by PGD2 alone to levels statistically equivalent to the 
controls. Incubation of HCF cells with selective DP2 receptor blocker BAYU3405 also did not 
significantly attenuate COX-2 expression as compared to controls. Co-incubation of HCF with 
PGD2 and BAYU3405 significantly down regulated COX-2 expression, equivalent to PGD2 
alone. 
Treatment with PGD2 did not affect the expression of COL 1A in HCF cells as compared 
to the untreated controls (Figure 12). Treatment with DP2 receptor activator 13, 14-dihydro-15-
keto PGD2 significantly elevated mRNA expression of COL 1A as compared to the controls. 
Upon treatment with DP2 receptor antagonist BAYU3405, the COL 1A mRNA expression was 
significantly higher than the controls and was also significantly lower than 13, 14 dihydro-15-
keto PGD2. Co-incubation with PGD2 and BAYU3405 significantly attenuated the PGD2 
mediated down-regulation of COL 3A. 
COL3A levels were unaltered by PGD2 treatment as compared to untreated controls 
(Figure 13). COL3A mRNA levels were significantly down-regulated upon treatment with the 
DP2 receptor agonist 13, 14 dihydro-15-keto-PGD2 as compared to untreated controls. Treatment 
with DP2 receptor antagonist BAYU3405 did not alter COL3A expression but Co-incubation 
with BAYU3405 and PGD2 significantly elevated COL3A mRNA expression.  
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Figure 13: DP2 receptor mediated effects on COL 3A mRNA expression. 
 
 
Figure 14: Comparison of Collagen 3A mRNA expression in control, PGD2 treated HCF cells, 
DP2 receptor agonist (13, 14 dihydro-15-keto PGD2), DP2 receptor blocker (BAYU3405), 
BAYU3405+ PGD2 10
-7
. Values reported as mean ±SEM. n ≥ 5 per group. * = p<0.05 vs. 
control and # = p<0.05 vs. PGD2 10
-7
. 
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Discussions: 
COX-2 enzyme expression was significantly down regulated by selective DP2 agonism, 
similar to treatment with PGD2 alone suggests this that activating of DP2 receptor leads to a 
negative feedback to COX-2 expression. DP2 receptor antagonism had no effect on COX-2 
expression which further supports the hypothesis of a negative feedback loop. Interestingly, co-
incubation with PGD2 and a DP2 receptor agonist attenuated the COX-2 expression down-
regulation by either treatment alone. This might be due to over stimulation of DP2 receptor by 
PGD2, 13, 14-dihydro-15-keto PGD2 and 15–d PGJ2. As previously mentioned 15 – d PGJ2, the 
non enzymatic downstream product of PGD2 is known to have higher affinity to DP2 receptor 
than its endogenous receptor PPAR-HFC cells treated the DP2 antagonist, with no lone 
activity on COX-2 expression, and PGD2 led to the same decrease in COX-2 expression as PGD2 
alone. This might be due to the action of PGD2 on the uninhibited DP1 receptors.     
The DP2 antagonist alone did not alter collagen expression but the combination of the 
agonist and PGD2 counter the intuitively increased COL 3A expression. COL 3A levels on the 
other hand were found to be significantly down regulated upon DP2 receptor activation. DP2 
receptor antagonism does not alter COL3A mRNA expression. Co incubation with DP2 receptor 
antagonist with PGD2 led to significant up regulation of COL3A mRNA expression. This, 
transcriptional up-regulation could be due to inhibition of the down regulation of COL3A 
expression associated with DP2 receptor activation leading to elevation of COL3A expression via 
PGD2 mediated activation of DP1 receptors. COL1A is known to be of higher tensile strength as 
compared to COL1A. Thus, ratio of levels of COL 1A to 3A plays a vital role in determining the 
myocardial wall thickness and compliance. Our own data demonstrated that activation of DP1 
receptors increased both COL1A and COL3A mRNA expression leading to fibrosis. We further 
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showed that activation of DP2 receptors led to an increase in COL1A and decrease in COL3A 
resulting in altered ratio between COL1A and COL3A. This could potentially lead to reduced 
compliance and increased stiffness of the left ventricle as seen in ventricular fibrosis. 
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Figure 15: Schematic diagram depicting role of COX-2 and PGD2 on maladaptive left ventricular 
remodeling. 
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SYNOPSIS: 
 
Chronic hypertension has long been known to cause left ventricular remodeling which 
progresses into dilated cardiomyopathy and finally resulting in heart failure[66]. Although 
previous studies pointed towards inflammation[13,14,15] as the pathological driving force for 
cardiac remodeling. The exact mechanistic pathway associated with pressure overload-induced 
cardiac remodeling remains to be elucidated. 
Numerous studies were done to evaluate the role of COX activity and inhibition on 
cardiac remodeling in models of infarction and heart failure[23,24]. Our study sought to 
understand the role of inflammatory regulator COX-2 in mediating pressure overload induced 
left ventricular remodeling.  The results demonstrated that COX-2 plays a vital role in mediating 
the two main aspects of LV remodeling, ventricular hypertrophy and extracellular matrix 
remodeling. In a whole animal model of PO, selective inhibition of COX-2 with Nimesulide 
significantly prevented initial ventricular maladaptive remodeling in particular LV mass, 
EDPVR, Tau etc (Figure 14). In this study, pressure overload induced cardiac remodeling was 
associated with elevated H-PGD synthase, suggesting that PGD2 in particular, out of all the 
molecules down-stream of COX-2 plays an important role in pressure overload-induced LV 
remodeling. Chronic COX-2 inhibition was associated with renal and cardiovascular 
complications during chronic use[25,26]. Therefore it was essential to establish a timeline for 
COX-2 inhibitory benefit and to understand the potential long terms beneficial effects associated
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with the acute treatment with COX-2 inhibitors. Thus we examined both the long term benefit of 
early intervention and the efficacy of allowing PO induced cardiac remodeling and then 
inhibiting COX-2. In particular the preventative treatment strategy with Nimesulide was 
designed to assess potential long term beneficial effects post acute treatment during initial stages 
of remodeling. The results indicated that Nimesulide treatment successfully attenuated various 
aspects of maladaptive remodeling and the beneficial effects were significant even after the 
discontinuation of treatment. In order to understand the Nimesulide on potentially reversing 
already established remodeling the intervention treatment strategy was designed. The results 
from the intervention treatment with Nimesulide indicated that although certain function 
parameters were reversed, other complications like fibrosis as indicated by total myocardial 
collagen levels were not affected by intervention treatment with Nimesulide.   
The downstream mechanistic pathway beyond COX-2 inhibition involved was not clearly 
understood.  The beneficial effects associated with Nimesulide might be through one or more of 
its downstream prostaglandins. Previously reported studies and our results from COX-2 
inhibition suggested a role for PGD2 in preventing pressure overload-induced LV remodeling[40, 
42]. In particular, further prevention and intervention studies with an H-PGD synthase inhibitor 
(HQL 79) significantly attenuated maladaptive post PO remodeling and these effects were 
similar to selective inhibition of upstream COX-2 suggesting that beneficial effects associated 
with COX-2 inhibition are mediated via PGD2.  
It remained unclear that the particular receptor mediated changes in the cardiac 
fibroblasts that were responsible for ventricular remodeling whose blockade would be of highest 
potential for the therapeutic benefit, therefore the effects of specific agonists and antagonists of 
DP1 and DP2 were assessed.  
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Both DP1 and DP2 activation significantly down regulated HCF cell COX-2 expression, 
corresponding to the down regulation observed with PGD2 treatment. mRNA expression of both 
COL1A and COL3A upon selective DP1 receptor activation indicates that the DP1 receptor plays 
a vital role in elevation of total collagen levels leading to fibrosis.  . Specific DP2 receptor 
activation on the other hand was shown to alter the balance of COL1A to COL3A in favor of 
Col1A, this could lead to altered LV tissue properties including loss of compliance and relation 
properties of the LV. These results indicate that the PO mediated fibrosis was possibly due to 
elevated PGD2 levels which act via DP1 and DP2 receptors. 
The selective COX-2 inhibition studies (AIM 1 and 2) demonstrated that acute COX-2 
inhibitors treatment during the initial stages of remodeling might have significant clinical 
therapeutic potential to prevent or reverse various LV structural and functional parameters 
associated with hypertension induced cardiac remodeling. These result indicate that, Nimesulide 
treatment can be incorporated into the usual anti hypertensive treatment regime for patients 
diagnosed with hypertension, to attenuate early LV remolding, Nimesulide treatment can be later 
discontinues after the hypertensive stress is brought under control. This strategy would help 
prevent maladaptive remodeling in the early stages of hypertensive stress.  The selective H-PGD 
synthase inhibition study in rats and the In vitro assessment of PGD2 mediated effects of human 
cardiac fibroblasts (AIM 4) suggest that PGD2 plays a vital role in mediating PO induced cardiac 
remodeling. Thus, specific inhibition of H-PGD synthase and/ or Prostaglandin receptors might 
prove to be novel therapeutic targets which could have profound clinical significance in 
preventing and reversing maladaptive LV remolding induced by hypertension without 
precipitating the adverse effects associated with global prostaglandin inhibition.   
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